Saturday, March 6, 2021
Home Latest Pharma-News EU approves Tukysa Combo for Advanced HER2-Positive Breast Cancer

EU approves Tukysa Combo for Advanced HER2-Positive Breast Cancer

Febuary: “Seagen’s Tukysa (tucatinib) has been approved by the European Commission as part of a triple-combination therapy for people with previously treated advanced or metastatic HER2-positive breast cancer.

The EC approved Tukysa, when given alongside trastuzumab and the chemotherapy medication Xeloda (capecitabine), for patients who have received at least two anti-HER2-based treatments for metastatic disease.

- Advertisement -

With this decision, Seagen — previously known as Seattle Genetics — will be able to market the Tukysa combo in all European Union (EU) member states, plus Norway, Liechtenstein, Iceland, and Northern Ireland.

“We are pleased Tukysa is now approved in Europe, and we look forward to further collaborating with individual countries to ensure it is available to patients,” Clay Siegall, PhD, CEO at Seagen, said in a press release.

The U.S. FDA approved Tukysa for the same indication in May 2020.

In December 2020, the Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, also had supported Tukysa’s approval in the EU.

“This approval is a significant advancement for patients in Europe, who will for the first time have an approved medicine demonstrating a survival benefit for HER2-positive metastatic breast cancer after disease progression following two standard anti-HER2 treatment regimens,” said Volkmar Mueller, MD, deputy director at the University Medical Center Hamburg-Eppendorf, in Germany, a trial investigator.”

https://breastcancer-news.com/2021/02/15/tukysa-combo-approved-europe-advanced-her2-positive-breast-cancer/

LEAVE A REPLY

Please enter your comment!
Please enter your name here

18 + 16 =

Most Popular

FDA Authorizes Adaptive Biotechnologies T-Detect COVID Test

March 05, 2021: "The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the T-Detect COVID Test developed by...

EMA issues advice on Lilly’s bamlanivimab with etesevimab for confirmed COVID-19 in EU

March 5, 2021: "Eli Lilly and Company announced that the EMA Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific opinion...

MHRA says modified COVID-19 vaccines for variants to be fast-tracked

March 04, 2021: "Authorised COVID-19 vaccines that are modified in response to new variants will not need a brand new approval or “lengthy” clinical studies,...

Co-WIN Covid-19 vaccine registration prosess

Co-WIN Covid-19 vaccine registration: The registrations for the Covid-19 vaccine registration opened from 9 AM on March 1 till 3 PM every...